|1.||Dohi, Toshihiro: 2 articles (01/2014 - 10/2004)|
|2.||Morita, Katsuya: 2 articles (01/2014 - 10/2004)|
|3.||Kurata, Yasutaka: 2 articles (12/2007 - 12/2005)|
|4.||Shibamoto, Toshishige: 2 articles (12/2007 - 12/2005)|
|5.||Cui, Sen: 2 articles (12/2007 - 12/2005)|
|6.||Kitayama, Tomoya: 1 article (01/2014)|
|7.||Motoyama, Naoyo: 1 article (01/2014)|
|8.||Kanematsu, Takashi: 1 article (01/2014)|
|9.||Shiraishi, Seiji: 1 article (01/2014)|
|10.||Uezono, Yasuhito: 1 article (01/2014)|
10/01/2000 - "Furthermore, the mean APACHE-II score during treatment with TCV-309 was significantly lower and the number of patients recovered from shock after day 14 was significantly higher in the TCV-309 treated patient group (2/32 vs. 9/29, P = 0.01). "
04/01/1995 - "These results suggested that TCV-309 was a useful therapeutic for the circulatory disturbance in endotoxin shock."
05/01/1994 - "Effects of TCV-309, a novel PAF antagonist, on circulatory shock and hematological abnormality induced by endotoxin in dogs."
04/01/1995 - "The results showed that the depression of mean aortic pressure, cardiac output, left ventricular stroke work index and urine volume which occurred in endotoxin shock was significantly improved by administration of TCV-309. "
01/01/1995 - "Pretreatment with TCV-309 inhibited the shock that ultimately occurred in the untreated rats; the survival rate 16 h after hepatic ischemia was 20% in the untreated control group but 100% in the group pretreated with TCV-309. "
|2.||Systemic Inflammatory Response Syndrome (Sepsis Syndrome)
05/01/1996 - "Treatment with TCV-309 appears to be safe in patients with systemic inflammatory response syndrome and does improve organ failure significantly."
05/01/1996 - "In a prospective randomized, double-blind, placebo-controlled clinical study, the safety and efficacy of the platelet-activating factor antagonist TCV-309 in the treatment of systemic inflammatory response syndrome was studied. "
05/01/1996 - "Treatment with the platelet-activating factor antagonist TCV-309 in patients with severe systemic inflammatory response syndrome: a prospective, multi-center, double-blind, randomized phase II trial."
05/01/1999 - "Pancreatitis rats were treated with a bolus intravenous injection of TCV-309 (3 or 30 micrograms/kg) 30 min before the septic challenge. "
05/01/1999 - "The PAF antagonist TCV-309 effectively prevented hyperactivity of bronchoalveolar macrophages and pancreatitis-associated lung injury after the septic challenge."
05/01/1999 - "Pancreatitis rats treated with TCV-309 had lower serum concentrations of CINC after septic challenge and lower levels of CINC messenger RNA (mRNA) in the lung, as well as fewer pulmonary infiltrates immunoreactive for CINC or Mac-1 (CD11b/CD18). "
12/01/1992 - "TCV-309, a selective PAF antagonist, administered prior to caerulein and/or PAF, reduced caerulein-induced pancreatitis and prevented PAF-induced pancreatitis. "
05/01/1999 - "Intense mononuclear cell infiltration and lung hemorrhage occurred in pancreatitis rats complicated with sepsis but were not seen in pancreatitis rats receiving a bolus TCV-309. "
09/01/2013 - "An analysis of the mode of anti-allodynia action of TCV-309 in vivo revealed a competitive action against PAF shortly after the injection of TCV-309, converting to a non-competitive action later. "
10/01/2004 - "Tactile allodynia induced by PAF was blocked by a PAF receptor antagonists, TCV-309, WEB 2086 and BN 50739. "
01/01/2014 - "Chemical structurally different type of antagonists, TCV-309, BN 50739 and WEB 2086 ameliorated the allodynia and improved pain behaviors such as guarding behavior and limb-use abnormalities in FBC model mice. "
09/01/2013 - "PAF antagonists, TCV-309, BN 50739 and WEB 2086 by intravenous (i.v.) and oral administration have potent and long-lasting anti-allodynia action in mice neuropathic pain models. "
|1.||Platelet Activating Factor
|2.||WEB 2086 (apafant)
|2.||Surgical Portasystemic Shunt (Portosystemic Shunt)